🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 45773H409 (prev. 45773H102 )
- Market Cap
- Small Cap
- Previous Symbol
- GEB (changed 4/4/2005)
- Previous Name
- Genetronics Biomedical Ltd
Business: Inovio Pharmaceuticals, Inc. is engaged in the development of a new generation of vaccines, called synthetic vaccines, focused on cancers and infectious diseases. The Company's SynCon technology enables the design of universal vaccines capable of providing cross-protection against existing or changing strains of pathogens, such as influenza and human immunodeficiency virus (HIV).
Notes: Jan. 23, 2024 -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that a 1-for-12 reverse stock split of its outstanding shares of common stock will be effective as of 5:00 p.m. Eastern Time on Wednesday, January 24, 2024. The company's common stock will begin trading on a reverse stock split-adjusted basis at the opening of the market on Thursday, January 25, 2024. Following the reverse stock split, the company's common stock will continue to trade on the Nasdaq Capital Market under the symbol "INO" with the new CUSIP number, 45773H409. The reverse stock split is part of the company's plan to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
Company Contact
- CEO
- Jacqueline Shea
- CFO
- Peter Kies
- Headquarters
- 660 W. Germantown Pike, Suite 110, Plymouth Meeting, PA 19462
- Phone
- 267-440-4200 · Toll-Free 877-446-6846
- Fax
- 267-440-4242
- Investor Relations
- Thomas Hong · 267-440-4298 · thomas.hong@inovio.com